To conduct a synthesis of existing empirical and grey literature to identify the contexts and mechanisms that enable the adoption, offer, uptake and return of faecal immunochemical testing (FIT) in the primary care pathway in England, UK, for patients with signs or symptoms of suspected colorectal cancer (CRC). From this, develop a theory about how specific programme activities lead to certain outcomes.
A realist synthesis.
Medline (OVID), EMBASE (OVID), CINAHL (EBSCO), Scopus (Elsevier) and grey literature sources until end of July 2023.
The purpose of the work was to determine how different factors interact within a health system to optimise the approach to implementing and using symptomatic FIT (sFIT) in clinical practice for patient benefit. The criteria used to bound the scope of the synthesis included date (published between 2017 and July 2023), exposure of interest (sFIT in the primary care pathway for patients with signs or symptoms of suspected CRC), geographic location of study (countries that make up the UK), language (English) and participants (adults). Any study design and type of publication was considered.
Given the recognised lack of literature on the implementation of sFIT, it was crucial to include insights from grey literature. To do this, key national groups and organisations—involved or related to this subject—were methodically identified and appropriate papers and reports identified.
A thematic approach was used to identify relevant data in included records and allow realist insights to be obtained. Inductive and deductive coding enabled detection of key data. Arguments were generated and developed into context–mechanism–outcome configurations (CMOCs). Iteratively, an initial list of 38 CMOCs was refined to 14 themes and 19 CMOCs. These were then structured to create a multifaceted, multilevel realist synthesis programme theory.
Systematic searching led to the full appraisal of 99 records to determine suitability of each to confirm, refute or help develop theory. Studies were assessed for rigour and relevance to inform selection. The process resulted in 45 records being chosen for inclusion, of which 28 were from database searches and 17 from grey literature sources.
The key contexts and mechanisms that help optimise adoption, offer, uptake and return of sFIT have been elucidated (although partially). These can be broadly summarised into the 10 ‘Cs’: creating a compelling Case and Conditions for change, reaching Consensus through Collaborative working, fostering a Culture that values Clinical judgement, building Confidence by developing Capabilities and, finally, ensuring Clarity and Coherence of both practical processes and safety netting procedures.
Fundamentally, optimising the adoption, offer, uptake and return of sFIT in primary care for patients with signs or symptoms of suspected CRC is predicated on developing the acceptability of this initiative to every stakeholder at every level within a health system.
The rapid growth in the cancer survivor population in Chile and Latin America raises new challenges in addressing their care needs. This study assesses the health status and compares the quality of care and quality of life in cancer survivors at a primary care network and a private cancer centre in Santiago, Chile.
Retrospective cohort study.
Three primary care clinics and one cancer centre in Chile.
All breast and colorectal cancer patients identified from a primary care retrospective cohort of 61 174 were followed from 2018 to 2023 and compared with an equivalent sample of patients from a university cancer centre identified during the same period.
Quality of care was assessed based on American Cancer Society standards, while quality of life was measured using the EuroQol 5 Dimensions-5 Levels survey instrument.
A total of 420 cancer survivors participated in the study; 208 from primary care and 212 from the cancer centre. All participants received substandard care. Patients in primary care had lower educational levels and higher rates of comorbidity. They reported a lower quality of life score (72.22 vs 78.43, p
Cancer survivors face a significant disease burden and receive substandard care in Chile. As the primary source of care for this population, primary care is challenged to better integrate with speciality care to develop an effective shared care model for cancer survivors.
We calculate positive predictive values (PPVs) of patients presenting with unexpected weight loss (UWL) being diagnosed with cancer within 6 months, using data from a population of Australian primary care patients to replicate results from a previous UK study.
A diagnostic accuracy study involving calculation of the PPV for any cancer using retrospective data from routinely collected electronic healthcare records. The index date is defined as the first recorded UWL presentation and the reference standard is cancer diagnosis within 6 months of the index date.
This study uses primary care data from the Patron primary care database, linked to hospital admissions data and the Victorian Cancer Registry. We include only patients who presented to their General Practitioners (GPs) at least once between 1 July 2007 and 1 February 2022.
Patients were included if they were at least 18 years of age at the index date, had no previous diagnosis of cancer or previous weight loss intervention, including being prescribed medications for weight loss. 13 306 patients out of a primary care population of 1 791 051 patients were identified that met the eligibility criteria.
When stratified by age, sex and smoking status, we found PPVs lower than those derived in a previous UK primary care study, though still above 3% for male non-smokers over 60, female smokers over 70 and all males over 70. Patients from ages 60–79 with at least one abnormal blood test result had PPVs consistently above 3%, while overall, patients with abnormal blood test results have PPVs of up to 35%.
We confirmed that many PPVs, while consistently below those derived in the UK study, are above clinically significant thresholds and increasing with age and the number of different abnormal blood test results.